March 1, 2023

Delivering cancer care from the first diagnosis is a team approach. Each step affects downstream processes.

Pixatimod and nivolumab showed benefits for patients with microsatellite-stable metastatic colorectal cancer.

Neoadjuvant chemotherapy with carboplatin has been shown to improve the pathologic complete response rate for patients with triple negative breast cancer.

In the NORA study, a 16% reduction in the risk of death was achieved with maintenance niraparib in patients with platinum-sensitive recurrent ovarian cancer.

Acquired resistance to BTK inhibitors is a new and growing challenge in the treatment of CLL and dual resistance to BTK and BCL2 is occurring in more patients, according to Lindsey Roeker, MD.

The triplet regimen acalabrutinib, venetoclax, and obinutuzumab in the frontline chronic lymphocytic leukemia setting was highly active and well tolerated demonstrating durable responses.

Phase 2 findings support a phase 3 investigation of neoadjuvant SHR-1701 as combination therapy for untreated stage III unresectable non–small cell lung cancer.

High-dose IL-2 is approved for use as a single agent in patients with metastatic melanoma. However, the agent induces limited efficacy and is known to have considerable toxicity.

Medically integrated dispensing pharmacies in oncology often deal with complex PAs that can inhibit delivery of timely, quality care and consume staff resources.

the tremendous scientific developments in ctDNA, including genetic and epigenetic alterations, which are detectable in the blood—the so-called liquid biopsy—or multicancer early detection tests, represent a revolution that seems to be rapidly emerging on the horizon.

In the wave of its major influence on these malignancies, anti-HER2 therapy for various cancers—notably colorectal cancer —has been thoroughly investigated.